BRAF/MEK inhibitors use for pediatric gliomas; real world experience from a resource-limited country
Our experience with BRAF/MEK inhibitors' use was positive achieving response in all LGGs and provided sustained response with good quality of life for patients with HGG. Cost effectiveness analyses and patients' satisfaction comparisons with chemotherapy are needed to evaluate the routine use of these drugs in LMICs.
Authors
- Dima Abu Laban
- Maysa A. Al-Hussaini (ORCID: https://orcid.org/0000-0001-6392-150X)
- Nisreen Yousef Amayiri (ORCID: https://orcid.org/0000-0002-7972-5885)
- Mouness Obeidat (ORCID: https://orcid.org/0009-0009-2485-3845)
- Kawther Khaleifeh
- Awni Musharbash (ORCID: https://orcid.org/0000-0003-4785-1323)
- Bayan Maraqa (ORCID: https://orcid.org/0000-0001-9455-188X)
- Éric Bouffet (ORCID: https://orcid.org/0000-0002-6832-6539)
- Qasem Alzoubi
- Saad Jaddoua
- Raed Ramlawi
- A.K. Ibrahimi
- Nasim Sarhan (ORCID: https://orcid.org/0000-0002-7963-7498)
- Abeer Alsharif
Institutions
- King Hussein Cancer Center (JO)
- Hospital for Sick Children (CA)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-09-27
- DOI
- https://doi.org/10.3389/fonc.2024.1417484
- Citations
- 6
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.63